For patients with advanced cervical cancer, cisplatin plus pemetrexed may be effective
the ONA take:
According to a new study published in the Journal of Clinical Oncology, cisplatin plus pemetrexed improved response rates and survival rates of patients with advanced cervical cancer. In the phase 2 study, researchers assigned patients with advanced, persistent, or recurrent cervical cancer to received either cisplatin in combination with pemetrexed or paclitaxel.
Researchers found that patients with no prior history of chemotherapy that received cisplatin plus pemetrexed had a 31% response rate for a duration of up to 7 months and an overall survival of 12 months. Patients that received cisplatin plus paclitaxel had a 29% response rate for a duration of up to 6 months and an overall survival of 13 months.
Furthermore, the pemetrexed combination was observed to be less toxic compared with the paclitaxel combination. Researchers also observed increased survival rates when adding bevacizumab to the paclitaxel combination, so researchers suggest possibly adding bevacizumab to the pemetrexed combination.
According to the Centers for Disease Control and Prevention (CDC), cervical cancer used to be the leading cause of cancer-related death in women in the United States, but regular Pap screenings have led to early cancer detection and decreased mortality.
Cisplatin plus pemetrexed improved response rates in patients with advanced cervical cancer.
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.
The cancer-fighting cocktail, which combines the chemotherapy drug cisplatin with pemetrexed - an agent that stops cancer cells from dividing - showed promising results for advanced, persistent, or recurrent cervical cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|